ReviewJournal of diabetes and metabolic disorders2025
Non-HDL-C and non-HDL-C/HDL-C ratio as predictors of hepatic steatosis: a systematic review and meta-analysis.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association Between Cardiometabolic Index and Liver Fibrosis: Mediation Analysis of Oxidative Stress Factors.Anatolian journal of cardiology · 2026Article
- Association between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with HIV on dolutegravir-based antiretroviral therapy: A cross-sectional study in Southwestern Uganda.BMC research notes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association between novel atherogenic indices (NAIs) and the pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD) has been extensively researched. Among these, non-high-density lipoprotein cholesterol (non-HDL-C) and non-HDL-C/HDL-C ratio are novel indices linked to a higher risk for metabolic syndrome - and possibly MASLD. The current review evaluates the possible utility of these NAIs as markers for MASLD. Materials and methods: MEDLINE, Scopus, and Web of Science were systematically searched. Screening and data extraction were performed by two independent reviewers. All observational studies reporting standardized mean differences (SMD), odds ratios (ORs) and components of receiver operating characteristic (ROC) analysis were included in evidence synthesis. Meta-analysis was performed using a random effects model. Results: 34 studies were included in the quantitative synthesis. Non-HDL-C (SMD = 1.11, 95% CI 0.49-1.73) and non-HDL-C/HDL-C (SMD = 0.77, 95% 0.55-0.98) were significantly higher in MASLD patients. Similarly both indices were associated with increased odds for development or diagnosis of MASLD (non-HDL-C OR = 1.34, 95% CI 1.19-1.48; non-HDL-C/HDL-C OR = 1.68, 95% CI 1.30-2.04). Non-HDL-C (AUC = 0.68, 95% CI 0.65-0.72) and non-HDL-C/HDL-C demonstrated "good" utility (AUC = 0.74, 95% CI 0.70-0.77) as a diagnostic marker for MASLD. Conclusion: Our findings showed a significant association between these NAIs and MASLD. Both non-HDL-C and non-HDL-C/HDL-C ratio also showed an acceptable performance as biomarkers for MASLD. The use of these NAIs as part of a complex model for prediction of MASLD may prove even more beneficial in the clinical setting. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01719-0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.